Reunion Neuroscience

Executive Summary

Reunion Neuroscience is a clinical-stage biopharmaceutical company developing novel serotonergic psychedelic therapies for underserved mental health conditions. Its lead candidate targets postpartum depression, with additional programs for adjustment disorder and generalized anxiety disorder. The company aims to provide fast-acting, short-duration treatments that offer durable, potentially curative outcomes beyond symptom management. As a private entity, Reunion is positioned to address significant unmet needs in mental health, with its Phase 2 assets representing near-term value inflection points. The company's differentiated approach and focus on safety and efficacy could drive interest from strategic partners or investors.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 topline data for lead postpartum depression candidate60% success
• 2027Initiation of Phase 3 trial for lead indication70% success
• TBDPotential partnership or licensing deal for non-lead indications40% success